Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Hold at Scotiabank

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by investment analysts at Scotiabank to a “hold” rating in a report released on Wednesday,Zacks.com reports.

Several other equities research analysts have also weighed in on the company. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 price target on the stock. Citigroup upped their price objective on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, November 9th. Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Finally, Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $789.91.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $694.99 on Wednesday. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $73.04 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $803.41. The firm’s 50-day moving average price is $596.36 and its two-hundred day moving average price is $570.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same period last year, the company earned $12.46 EPS. The business’s quarterly revenue was up .9% compared to the same quarter last year. As a group, equities analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.02% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of REGN. Vanguard Group Inc. raised its stake in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after purchasing an additional 121,545 shares during the period. State Street Corp grew its stake in Regeneron Pharmaceuticals by 0.9% during the second quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after acquiring an additional 42,343 shares in the last quarter. Dodge & Cox boosted its holdings in shares of Regeneron Pharmaceuticals by 18.9% during the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after purchasing an additional 724,562 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Regeneron Pharmaceuticals by 6.0% in the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock worth $1,379,329,000 after buying an additional 139,647 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock worth $1,379,467,000 after acquiring an additional 89,579 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.